According to Titos et al., RvD1 can treat obesity-related insulin resistance and other metabolic complications, reducing adipose tissue inflammation by lowering the concentrations of cytokines and adipokines (TNF-α, IL-6, IL-8, IL-1β, MCP-1), and reducing inflammation in obesity-induced NASH [27,28]. This evidence concerns the gene CXCL8 and metabolic dysfunction-associated steatohepatitis.